Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Fairooz Kabbinavar"'
1
Akademický článek
HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
Autor: Farbod Shojaei, Bob Goodenow, Gloria Lee, Fairooz Kabbinavar, Mireille Gillings
Publikováno v: Frontiers in Oncology, Vol 11 (2022)
HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are c
Externí odkaz: https://doaj.org/article/6ca3c477813b4ec98437d652ef9e477d
Zobrazit plný text záznamu
3
Akademický článek
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Autor: Ferdows Ather, Habib Hamidi, Marlena S Fejzo, Stephen Letrent, Richard S Finn, Fairooz Kabbinavar, Christian Head, Steven G Wong
Publikováno v: PLoS ONE, Vol 8, Iss 2, p e56112 (2013)
Aberrant epidermal growth factor (EGF) signaling is associated with tumor growth in squamous cell carcinoma of the head and neck in humans (HNSCC), and is a major focus of targeted therapy. Cetuximab, a monoclonal antibody against EGFR, has been succ
Externí odkaz: https://doaj.org/article/0d27ed6e915e449086ccc8c6a5696e09
Zobrazit plný text záznamu
4
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database
Autor: Jan Franko, Jun Yin, Richard A. Adams, John Zalcberg, Jack Fiskum, Eric Van Cutsem, Richard M. Goldberg, Herbert Hurwitz, Carsten Bokemeyer, Fairooz Kabbinavar, Alexandra Curtis, Jeffery Meyers, Benoist Chibaudel, Takayuki Yoshino, Aimery de Gramont, Qian Shi
Publikováno v: European Journal of Cancer. 174:142-152
Higher body mass index is associated with a higher incidence of colorectal cancer (CRC) but also with improved survival in metastatic CRC (mCRC). Whether weight change after mCRC diagnosis is associated with survival remains largely unknown.We analys
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b9f27e4dcc457dfef67093938ab81
https://doi.org/10.1016/j.ejca.2022.07.021
Zobrazit plný text záznamu
5
Abstract LB526: HBI-2375, a selective inhibitor of MLL1-WDR5 interaction, possesses desirable preclinical characteristics to be pursued in IND enabling studies and future clinical investigations
Autor: Farbod Shojaei, J E. Semple, Che Fang, Jill M. Ricono, Fairooz Kabbinavar, Bob Goodenow, Mireille Gillings
Publikováno v: Cancer Research. 82:LB526-LB526
92130MLL1 (mixed lineage leukemia1) interaction with WDR5 (WD repeat domain 5) is critical for MLL1 histone methyl transferase (H3K4me) activity leading to transcriptional regulation of gene expression. MLL1 dysregulation such as its translocation at
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11212f374e997646a3ff451b34808b74
https://doi.org/10.1158/1538-7445.am2022-lb526
Zobrazit plný text záznamu
6
Abstract 1041: HBI-2376, HUYABIO clinical stage SHP2 inhibitor, possess robust in vitro potency and in vivo efficacy in several preclinical tumor models carrying KrasG12C or EGFR mutations
Autor: Farbod Shojaei, Jill M. Ricono, Che Fang, Fairooz Kabbinavar, Bob Goodenow, Mireille Gillings
Publikováno v: Cancer Research. 82:1041-1041
SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2) is an attractive target in oncology drug development due to its dual roles on the direct growth and proliferation of cancer cells and also acting as an immune checkpoint molecule
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9caa5d4286df53e1c12847a34f9fe92
https://doi.org/10.1158/1538-7445.am2022-1041
Zobrazit plný text záznamu
9
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
Autor: Fred R, Hirsch, Fairooz, Kabbinavar, Tim, Eisen, Renato, Martins, Fredrick M, Schnell, Rafal, Dziadziuszko, Katherine, Richardson, Frank, Richardson, Bret, Wacker, David W, Sternberg, Jason, Rusk, Wilbur A, Franklin, Marileila, Varella-Garcia, Paul A, Bunn, Ross, Camidge, D Ross, Camidge
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26)
Purpose Erlotinib prolongs survival in patients with advanced non–small-cell lung cancer (NSCLC). We report the results of a randomized, phase II study of erlotinib alone or intercalated with chemotherapy (CT + erlotinib) in chemotherapy-naïve pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d385ecdb50fc1270684ddd281cecd6f8
https://pubmed.ncbi.nlm.nih.gov/21825259
Zobrazit plný text záznamu
10
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma
Autor: Patrick, Schöffski, Jorge A, Garcia, Walter M, Stadler, Thierry, Gil, Eric, Jonasch, Scott T, Tagawa, Melanie, Smitt, Xinqun, Yang, Kelly S, Oliner, Abraham, Anderson, Min, Zhu, Fairooz, Kabbinavar
Publikováno v: BJU international. 108(5)
• To evaluate the efficacy and safety of single-agent AMG 102, an investigational, fully human monoclonal antibody to hepatocyte growth factor/scatter factor (HGF/SF), in renal cell carcinoma (RCC).• This open-label phase II study included patien
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cdc5e79e0e3a21e751f63f7fef28d0f4
https://pubmed.ncbi.nlm.nih.gov/21156020
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje